Have you seen this?: Germline Testing in Women over 65

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

Have you seen this? 

Hereditary Cancer Testing for Women Over 65

October 20, 2021

DELRAY BEACH, FL – As a result of their age, women over the age of 65 years old, who are diagnosed with breast cancer, are usually not offered hereditary cancer genetic testing. Guidelines and recommendations from organizations, like the National Comprehensive Cancer Network are centered on the idea that this group of women has less than a 2.5% chance of having one pathogenic variant in a high-penetrance cancer risk gene. However, a recent study by the Mayo Clinic Cancer Center suggests that women with breast cancer over the age of 65, and all breast cancer patients, should be offered testing, not matter their age.

 

The study, published in the Journal of Clinical Oncology, found that 3.18% of women over the age of 65 diagnosed with breast cancer had pathogenic variants in a cancer predisposition gene, which is much higher than the 2.5% guideline threshold.1 The greatest prevalence of variations was found in BRCA1/2, PALB2, and CHEK2. This study also observed other subsets of this group were higher than the threshold of 2.5%, including women diagnosed with ER-negative breast cancer, 3.42%, and triple-negative breast cancer, 3.01%.

 

The corresponding author and principal investigator, Dr. Fergus Couch, stated, “As the 2.5% frequency is often used to trigger genetic testing, these results suggest that all women with estrogen receptor-negative breast cancer – and perhaps all women with breast cancer, including those diagnosed over age 65 – should be offered hereditary breast cancer testing.”2

 

Women with their germline variation results may benefit from targeted treatments, therapies and prevention strategies associated with secondary breast and other cancers. Dr. Couch also implored that, “We were not sure what this study of the older breast cancer population would yield, but our results support broader testing, regardless of age or family history.”2

  1. Boddicker NJ, Hu C, Weitzel JN, et al. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women [published online ahead of print, 2021 Jul 22]. J Clin Oncol. 2021;JCO2100531. doi:10.1200/JCO.21.00531
  2. Henderson E. Study: Women with breast cancer diagnosed over 65 should be offered hereditary cancer genetic testing. News-Medical. https://www.news-medical.net/news/20210722/Study-Women-with-breast-cancer-diagnosed-over-65-should-be-offered-hereditary-cancer-genetic-testing.aspx. Published July 23, 2021. Accessed October 14, 2021.

Genetics Institute

Genetics Institute of America is a national laboratory dedicated to heightening the awareness of early intervention and genetic screening to promote longevity and quality of life outcomes by focusing on DNA, RNA and Proteins. Our modern CLIA laboratory facility in Delray Beach, FL contains the most current technology, allowing us to provide leadership in both research and clinical laboratory testing. For more information, please visit http://www.GenLabUS.com/.

Leave a Reply

About Genetics Institute of America

Genetics Institute of America (GIA) is a national laboratory dedicated to heightening the awareness of early intervention and genetic screening to promote the longevity and quality of life outcomes.  

 

Follow Us

Educational Resources